Stock in news - Dr Reddy

Dr. Reddy's Laboratories' net sales (including other operating revenue) rose 19.89% to Rs 8528.4 crore. The Pharmaceutical Services segment's revenues, which make up 13.39% of total sales, increased by 1.29% to Rs 1,167.50 crore. The Global Generics category now accounts for 86.46% of total revenues, with sales growing 23.16% to Rs 7,536.50 crore. The Others segment's sales, which make up 0.15% of overall sales, have decreased by 90.70% to Rs 13.20 crore. From Rs 330.70 crore to Rs 211.20 crore, inter-segment sales decreased. At Rs 4,726.30 crore, profit before interest, tax, and other unallocable items (PBIT) has increased by 13.93%. The Pharmaceutical Services segment's PBIT increased by 7.15% to Rs 251.80 crore, or 5.33% of the overall PBIT. The Global Generics segment's PBIT increased 17.86% to Rs 4,470.70 crore, or 94.59% of the overall PBIT. The Others segment's PBIT dropped 96.83% to Rs 3.80 crore, or 0.08% of the overall PBIT. The Pharmaceutical Services segment's PBIT margin increased from 20.39% to 21.57%. The Global Generics segment's PBIT margin dropped from 61.99% to 59.32%. The Others segment's PBIT margin dropped from 84.51% to 28.79%. The overall PBIT margin decreased to 54.22% from 55.95%.